Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04827810 | A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer | suspended | Phase 1 | 42 | Fox Chase Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | suspended | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06549478 | Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases | suspended | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06500377 | Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer Survivors | suspended | N/A | 44 | City of Hope Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06581211 | Aromatherapy Oil Associated for Managing Anxiety and Pain During Bone Marrow Biopsy Procedures | suspended | N/A | 45 | City of Hope Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05279300 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | suspended | Phase 1 | 480 | CStone PharmaceuticalsINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | suspended | Phase 1 / Phase 2 | 81 | Children's Oncology GroupNETWORK | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06202066 | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas | suspended | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05155332 | A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | suspended | Phase 1 | 190 | Boehringer IngelheimINDUSTRY | 10 | Aug 19, 2026 | clinicaltrials |
| NCT04840589 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors | suspended | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05791448 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease | suspended | Phase 1 | 36 | University of Southern CaliforniaOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | suspended | — | 55 | Wake Forest University Health SciencesOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02962661 | Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines | suspended | Phase 1 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07176975 | A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers | suspended | Phase 1 | 46 | Boehringer IngelheimINDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors | suspended | Phase 1 | 100 | University of California, DavisOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03919292 | Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca | suspended | Phase 1 / Phase 2 | 83 | Virginia Commonwealth UniversityOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05101356 | A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma | suspended | Phase 1 / Phase 2 | 77 | University of California, DavisOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07395258 | A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | suspended | Phase 1 | 60 | Boehringer IngelheimINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04381806 | Phase I Study in Advanced Malignancies With 5-ALA | suspended | Phase 1 | 130 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery | suspended | — | 2,400 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT05206942 | Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy | suspended | N/A | 30 | Stanford UniversityOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05091632 | Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit | suspended | — | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03065062 | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | suspended | Phase 1 | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06508034 | Probiotics for the Prevention of Immunotherapy Induced Colitis in Patients Receiving Immunotherapy | suspended | N/A | 12 | Mayo ClinicOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05844306 | RefleXion PET/CT Imaging Performance in Patients With Various Malignancies | suspended | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05938296 | oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection | suspended | Phase 1 | 29 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04418167 | JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations | suspended | Phase 1 | 71 | JS InnoPharm, LLCINDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT05055518 | APL-102 Capsule in Patients With Advanced Solid Tumors | suspended | Phase 1 | 30 | Apollomics Inc.INDUSTRY | 1 | Jun 27, 2025 | clinicaltrials |
| NCT04485416 | Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors(CCPO011) | suspended | Phase 1 | 10 | University of California, DavisOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05416749 | A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors | suspended | Phase 1 / Phase 2 | 216 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05076591 | IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors | suspended | Phase 1 | 135 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT04946864 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | suspended | Phase 1 / Phase 2 | 65 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 19, 2024 | clinicaltrials |
| NCT03859752 | TR1801-ADC in Patients With Tumors That Express c-Met | suspended | Phase 1 | 15 | Open Innovation Partners, Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors | suspended | Phase 1 | 220 | Bellicum PharmaceuticalsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04042116 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | suspended | Phase 1 / Phase 2 | 227 | Clovis Oncology, Inc.INDUSTRY | 6 | Dec 20, 2022 | clinicaltrials |
| NCT03970382 | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | suspended | Phase 1 | 21 | PACT Pharma, Inc.INDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT03253575 | CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2(ANCERS-2) | suspended | — | 800 | Mitra RxDx, Inc.INDUSTRY | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00695032 | Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors | suspended | N/A | 80 | Institut Claudius RegaudOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT01762410 | Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors | suspended | Phase 1 | 60 | Piramal Enterprises LimitedINDUSTRY | 2 | Sep 29, 2014 | clinicaltrials |
| NCT01779336 | Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors | suspended | Phase 1 | 70 | Piramal Enterprises LimitedINDUSTRY | 2 | Sep 29, 2014 | clinicaltrials |
| NCT00003980 | BIBX 1382 in Treating Patients With Solid Tumors | suspended | Phase 1 | 80 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 11, 2012 | clinicaltrials |
| NCT01226056 | Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets | suspended | Phase 1 / Phase 2 | 45 | Southern Europe New Drug OrganizationOTHER | 1 | Oct 21, 2010 | clinicaltrials |
| NCT00827203 | A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors | suspended | Phase 1 | 30 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Mar 9, 2009 | clinicaltrials |
| NCT00460278 | Study of XL418 in Adults With Solid Tumors | suspended | Phase 1 | 63 | ExelixisINDUSTRY | 1 | Jun 4, 2008 | clinicaltrials |
| NCT00591682 | MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors | suspended | Phase 1 | 27 | Metastatix, Inc.INDUSTRY | 1 | Mar 26, 2008 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials